5-androstene-3β,17β-diol-3β-sulfate | 977-33-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 5-androstene-3β,17β-diol-3β-sulfate
• 英文别名: 5-androsten-3β,17β-diol-3-sulfate；androstenediol sulfate；3β-sulfooxy-androst-5-en-17β-ol；5-androstene-3β-17β-diol sulfate；[(3S,8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
• CAS: 977-33-3
• 化学式: C₁₉H₃₀O₅S
• 分子量: 370.51
• InChiKey: HXJFCUUBVWOORF-LOVVWNRFSA-N

物化性质

• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  92.2
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  雄烯二醇 在 吡啶 、 氯磺酸 、 氯仿 作用下， 生成 5-androstene-3β,17β-diol-3β-sulfate
  参考文献：
  名称：

  Cavina, Rendiconti - Istituto superiore di sanita, 1957, vol. 20, p. 923,934

  摘要：

  DOI：

文献信息

• REMEDY FOR HORMONE-DEPENDENT CANCER
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1568381A1

  公开（公告）日：2005-08-31

  A therapeutic agent for a hormone-dependent cancer, which comprises (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy, which may be administered together or separately at an interval, is provided. A method for treating a hormone-dependent cancer, which comprises administering (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy together or separately at an interval, is also provided. A steroid-sulfatase inhibitor which is used in combination with an agent for hormone therapy and/or an agent for chemotherapy, and which is administered together therewith or separately therefrom at an interval, is also provided. A kit for treating a hormone-dependent cancer, which comprises a first component comprising (a) a steroid-sulfatase inhibitor and a second component comprising (b) an agent for hormone therapy and/or an agent for chemotherapy, is also provided. A pharmaceutical composition, which comprises (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy, is also provided. Further, use of (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy for the manufacture of a therapeutic agent for a hormone-dependent cancer is provided.

  本发明提供了一种激素依赖性癌症的治疗剂，它包括(a)类固醇硫酸酯酶抑制剂和(b)激素治疗剂和/或化疗剂，这两种药物可以一起给药，也可以间隔一段时间分别给药。还提供了一种治疗激素依赖性癌症的方法，该方法包括(a)类固醇-硫酸酯酶抑制剂和(b)激素治疗制剂和/或化疗制剂，它们可以一起给药，也可以间隔一段时间分别给药。还提供了一种类固醇硫酸酯酶抑制剂，该抑制剂与激素治疗剂和/或化疗剂联合使用，并在一定间隔时间内一起或分开给药。还提供了一种用于治疗激素依赖性癌症的试剂盒，它包括由(a)类固醇硫酸酯酶抑制剂组成的第一组分和由(b)激素治疗剂和/或化疗剂组成的第二组分。还提供了一种药物组合物，它包含(a)类固醇硫酸酯酶抑制剂和(b)激素治疗剂和/或化疗剂。此外，还提供了使用(a)类固醇硫酸酯酶抑制剂和(b)激素治疗剂和/或化疗剂制造激素依赖性癌症治疗剂的方法。
• Use of dehydroepiandrosterone, its precursors and derivatives, by oral administration, as hydrating agents with direct action
  申请人：——

  公开号：US20030050293A1

  公开（公告）日：2003-03-13

  The invention concerns the use of at least a compound selected in the group consisting of dehydroepiandrosterone, its chemical precursors, its chemical derivatives, its biological precursors and metabolic derivatives, for preparing a composition designed for oral administration and for use to directly increase skin water content.

  本发明涉及至少一种选自脱氢表雄酮、其化学前体、其化学衍生物、其生物前体和代谢衍生物的化合物，用于制备口服给药组合物和直接增加皮肤含水量。
• Use of orally administered dehydroepiandrosterone, precursors and derivatives thereof in order to improve the papery aspect of the skin
  申请人：——

  公开号：US20030059451A1

  公开（公告）日：2003-03-27

  The use of at least one compound selected from the group consisting of dehydroepiandrosterone, the chemical precursors thereof, the chemical derivatives thereof, the biological precursors and metabolic derivatives thereof, in the production of a composition which can be administered orally and used in order to reduce or prevent the papery aspect of the skin.

  使用至少一种选自脱氢表雄酮、其化学前体、其化学衍生物、其生物前体和代谢衍生物组成的组的化合物，生产一种可口服的组合物，用于减少或防止皮肤的纸样化。
• Oral use of dehydroepiandrosterone and some of its derivatives as pigmentation regulators
  申请人：——

  公开号：US20030083323A1

  公开（公告）日：2003-05-01

  The invention concerns the use of at least a compound selected in the group consisting of dehydroepiandrosterone, its precursors and its metabolic derivatives, for preparing a composition for oral administration and for use in regulating human skin and/or skin appendages.

  本发明涉及至少一种选自脱氢表雄酮、其前体及其代谢衍生物的化合物，用于制备口服组合物和调节人体皮肤和/或皮肤附属物。
• Use of dehydroepiandrosterone and/or precursors or derivatives thereof to improve papery aspect of the skin
  申请人：——

  公开号：US20030124084A1

  公开（公告）日：2003-07-03

  The present invention relates to the use of DHEA and/or of at least one precursor or derivative thereof in or for the manufacture of a composition for topical application to the skin, as an agent for preventing or reducing the weathered appearance of the skin.

  本发明涉及 DHEA 和/或其至少一种前体或衍生物在皮肤外用组合物中的使用，或用于制造皮肤外用组合物，作为防止或减轻皮肤风化外观的制剂。